Kieffer Tara Lynn

Chief Product Strategy OfficerENANTA PHARMACEUTICALS INC (ENTA) · full profile →Form 4 · filed Feb 13, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
3 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 12, 2026Tax withholding(F)3K$14.25$46K34K
Feb 12, 2026Grant(A)5K$037K
Feb 12, 2026Grant(A)2K$032K

Transaction Codes

F
Shares withheld for taxes
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0002064832-26-000012) within minutes of acceptance. Every field above traces to the original document. Verify it directly: